Single-cell transcriptomes reveal the mechanism for a breast cancer prognostic gene panel

Shengwen Calvin Li*, Andres Stucky, Xuelian Chen, Mustafa H. Kabeer, William G. Loudon, Ashley S. Plant, Lilibeth Torno, Chaitali S. Nangia, Jin Cai, Gang Zhang, Jiang F. Zhong

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


The clinical benefits of the MammaPrint® signature for breast cancer is well documented; however, how these genes are related to cell cycle perturbation have not been well determined. Our single-cell transcriptome mapping (algorithm) provides details into the fine perturbation of all individual genes during a cell cycle, providing a view of the cell-cycle-phase specific landscape of any given human genes. Specifically, we identified that 38 out of the 70 (54%) MammaPrint® signature genes are perturbated to a specific phase of the cell cycle. The MammaPrint® signature panel derived its clinical prognosis power from measuring the cell cycle activity of specific breast cancer samples. Such cell cycle phase index of the MammaPrint® signature suggested that measurement of the cell cycle index from tumors could be developed into a prognosis tool for various types of cancer beyond breast cancer, potentially improving therapy through targeting a specific phase of the cell cycle of cancer cells.

Original languageEnglish (US)
Pages (from-to)33290-33301
Number of pages12
Issue number70
StatePublished - Sep 1 2018
Externally publishedYes


  • Cell cycle
  • Cell cycle phase
  • Cell-cycle-staged therapy
  • Single-cell
  • Transcriptome

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Single-cell transcriptomes reveal the mechanism for a breast cancer prognostic gene panel'. Together they form a unique fingerprint.

Cite this